^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TTX-810

i
Other names: TTX-810, ANJ810
Associations
Trials
Company:
Anji Pharma, Broad Institute
Drug class:
MCL1 inhibitor
Associations
Trials
over1year
ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models (AACR 2023)
ANJ810 induces efficient cancer cell killing within 4 hours in vitro but has no impact on cell viability or troponin I release in hiPSC-derived cardiomyocytes at supra-pharmacologic concentrations.In vivo, i.v. bolus injections of ANJ810 lead to short plasma residence time, yet are efficacious in xenograft models of multiple myeloma, DLBCL, NSCLC and HCC. ANJ810 will test the hypothesis in human clinical trials that short-term inhibition of MCL1 can overcome tumor resistance with an acceptable safety profile to improve current standard of care.
Preclinical • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1) • BAK1 (BCL2 Antagonist/Killer 1)
|
TTX-810